Medication info
Hwanin Memantin Orally Disintegrating Tablet 20 mg (Memantine Hydrochloride)

Hwanin Memantin Orally Disintegrating Tablet 20 mg (Memantine Hydrochloride)

Prescription medicationOrally disintegrating TabletOral
Ingredient · strength
Memantine Hydrochloride›20mg / 1 tablet
Manufacturer / importer
Hwanin Pharmaceutical Co., Ltd.
Appearance
White round orally disintegrating tablet
Packaging
90 tablets/box [(10 tablets/PTP × 9)]
Approval status
Active

MFDS item code 202400958 · Approved 2024.04.24

Summary

Main use
Treatment of moderate to severe Alzheimer's disease
Who takes it
Adults
Adult dose
This medicine is administered orally once daily, at the same time each day. If necessary, it may be administered twice daily. It may be taken with or without food. This is an orally disintegrating tablet. Place it on the tongue and allow it to dissolve; take without water. 1. Adults Dose escalation: The maximum daily dose is 20 mg. To minimize the risk of adverse reactions, increase the dose by 5 mg per week over the first 3 weeks as follows, reaching the maintenance dose: Week 1 (Days 1–7) Administer 5 mg once daily for 7 days. Week 2 (Days 8–14) Administer 10 mg once daily for 7 days. Week 3 (Days 15–21) Administer 15 mg once daily for 7 days. From Week 4 onward Administer 20 mg once daily. Maintenance dose: The recommended maintenance dose is 20 mg once daily. 2. Elderly patients: Based on clinical data, the recommended dose for patients aged 65 years and older is 20 mg once daily. 3. Patients with renal impairment: No dosage adjustment is necessary in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance 30-49 mL/min), reduce the daily dose to 10 mg. If well tolerated after at least 7 days of treatment, the dose may be increased to 20 mg once daily according to the standard dose-escalation schedule. In patients with severe renal impairment (creatinine clearance 5-29 mL/min), reduce the daily dose to 10 mg. 4. Patients with hepatic impairment: No dosage adjustment is necessary in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). As no data are available on the use of memantine in patients with severe hepatic impairment, administration of this medicine is not recommended.

Ingredients

Manufacturer
Hwanin Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of moderate to severe Alzheimer's disease

View approved original text

This medication is used for the treatment of moderate to severe Alzheimer's disease.

How to take

Adult dose

This medicine is administered orally once daily, at the same time each day. If necessary, it may be administered twice daily. It may be taken with or without food. This is an orally disintegrating tablet. Place it on the tongue and allow it to dissolve; take without water. 1. Adults Dose escalation: The maximum daily dose is 20 mg. To minimize the risk of adverse reactions, increase the dose by 5 mg per week over the first 3 weeks as follows, reaching the maintenance dose: Week 1 (Days 1–7) Administer 5 mg once daily for 7 days. Week 2 (Days 8–14) Administer 10 mg once daily for 7 days. Week 3 (Days 15–21) Administer 15 mg once daily for 7 days. From Week 4 onward Administer 20 mg once daily. Maintenance dose: The recommended maintenance dose is 20 mg once daily. 2. Elderly patients: Based on clinical data, the recommended dose for patients aged 65 years and older is 20 mg once daily. 3. Patients with renal impairment: No dosage adjustment is necessary in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance 30-49 mL/min), reduce the daily dose to 10 mg. If well tolerated after at least 7 days of treatment, the dose may be increased to 20 mg once daily according to the standard dose-escalation schedule. In patients with severe renal impairment (creatinine clearance 5-29 mL/min), reduce the daily dose to 10 mg. 4. Patients with hepatic impairment: No dosage adjustment is necessary in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). As no data are available on the use of memantine in patients with severe hepatic impairment, administration of this medicine is not recommended.

Precautions

This medication contains the artificial sweetener aspartame, which breaks down into phenylalanine in the body. Therefore, patients with the hereditary condition phenylketonuria should not take this medication. The daily intake of aspartame should be adjusted to not exceed 40 mg per kg of body weight, and for adults, a maximum of 2.4 g per day is considered safe. Patients who are hypersensitive to this medication, those with severe liver disease, and those with significantly diminished kidney function should not take this medication. Patients with epilepsy or a history of seizures should use this medication cautiously, and co-administration with certain NMDA antagonists should be avoided due to increased risk of side effects. Additionally, caution is advised in situations where urine acidity may change, in patients with recent myocardial infarction, heart failure, or uncontrolled hypertension. Side effects may include dizziness, headache, constipation, drowsiness, and hypertension, and psychiatric symptoms or seizures may occur in some patients. There may be interactions with other medications, so consultation with a doctor or pharmacist is required, especially when taking NMDA antagonists, antipsychotics, skeletal muscle relaxants, or anticoagulants. Women who are pregnant or may become pregnant should make a careful decision about taking this medication, as it may pose risks to the fetus, and breastfeeding women are advised to discontinue breastfeeding while using this medication. Safety and efficacy have not been established in children and adolescents under 18 years old, so it is advisable not to use it in this population. In case of overdose, severe symptoms such as coma, hallucinations, and seizures may occur, requiring immediate medical treatment, and since there is no specific antidote, symptomatic treatment is necessary. Finally, this medication may affect a patient's reaction time and concentration, so caution should be exercised while driving or operating machinery, and it should be stored out of reach of children and not transferred to other containers.

Side effects

  • Dizziness
  • headache
  • constipation
  • drowsiness
  • hypertension
  • fungal infection
  • drug hypersensitivity reaction
  • confusion
  • hallucinations
  • psychotic reactions
Show 24 more
  • balance disorder
  • gait abnormalities
  • seizures
  • heart failure
  • venous thrombosis/thromboembolism
  • dyspnea
  • vomiting
  • pancreatitis
  • elevated liver enzyme levels
  • hepatitis
  • fatigue
  • nonspecific fatigue
  • malaise
  • diarrhea
  • anxiety
  • aggression
  • stupor
  • unconsciousness
  • restlessness
  • psychosis
  • visual hallucinations
  • convulsions
  • coma
  • diplopia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a tightly closed container. Additionally, avoid extremely hot or cold places, and store at room temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

White round orally disintegrating tablet

Package unit

90 tablets/box [(10 tablets/PTP × 9)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.